Phase II study of FOLFIRI + cetuximab as induction chemotherapy followed by FOLFIRI + bevacizumab based on early tumor shrinkage in chemotherapy-naive patients with RAS wild-type colorectal cancer
Latest Information Update: 20 Aug 2021
At a glance
- Drugs Cetuximab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms HYBRID trial
- 03 Jul 2021 Results presented at the 23rd World Congress on Gastrointestinal Cancer
- 07 Jan 2019 Status changed from recruiting to discontinued.
- 08 Jan 2018 New trial record